世界卫生组织对BPaLM方案治疗耐多药结核病指南的解读
Interpretation of the World Health Organization guidelines for BPaLM regimens for the treatment of multidrug-resistant tuberculosis
段鸿飞1
作者信息
- 1. 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所结核科,北京 101149
- 折叠
摘要
耐多药结核病仍是人类健康的重大危险因素,近期世界卫生组织推荐贝达喹啉(bedaquiline,Bdq)、普托马尼(pretomanid,Pa)、利奈唑胺(linezolid,Lzd)和莫西沙星(moxifloxacin,Mfx)的6个月方案(BPaLM)治疗耐多药结核病.新指南中短程方案适用人群扩大到耐多药结核病患者,而且适用于病变广泛的肺结核和大多数肺外结核,无疑是耐多药结核病治疗的重要事件.本文就BPaLM方案的研究历程、适用人群和注意事项作一简要介绍.
Abstract
Multidrug-resistant tuberculosis(MDR-TB)remains a significant risk for human health,and the World Health Organization has recently recommended a 6-month treatment regimen(BPaLM)with bedaquiline(Bdq),pretomanid(Pa),linezolid(Lzd)and moxifloxacin(Mfx)to treat MDR-TB.The new regimen not only extend the short-course program to MDR-TB patients,but also apply to tuberculosis with extensive lesions and most extrapulmonary tuberculosis,which is undoubtedly an important event in the treatment of MDR-TB.This article briefly introduces research history,population and considerations of BPaLM regimen.
关键词
耐多药/利福平耐药结核病/短程治疗/世界卫生组织Key words
Multidrug-resistant/rifampicin-resistant tuberculosis/Short-course regimen/World Health Organization引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据